Sort   by:  
 Page size 
ProteomicsProteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer
Cancer precision medicine largely relies on knowledge about genetic aberrations in tumors and next-generation-sequencing studies have shown a high mutational complexity in many cancers. Although a large number of the observed mutations is believed to be not causally linked with cancer, the functiona...
ORGANISM(S): Homo sapiens (Human) 
2018-07-02 | PXD009996 | Pride
Lung cancer Proteomic System biology Drug resistance 
ProteomicsProteogenomic analysis unveils the expression of cancer associated and specific antigen-derived HLA Class ǀ immunopeptides in melanoma and EGFR mutant lung adenocarcinoma
Immunotherapy has shown great therapeutic potential for cancers with high tumor mutational burden (TMB), but much less promise for cancers with low TMB. One primary approach for adoptive lymphocyte transfer-based immunotherapy is to target the somatic mutated peptide neoantigens and cancer testis (C...
ORGANISM(S): Homo sapiens (Human) 
2021-12-07 | PXD019774 | Pride
Hla immunopeptidome Immunotherapy Neoantigen Melanoma Lung cancer 
TranscriptomicsGene amplification of the transcription factor DP1 and the CTNND1 in human lung cancer
The search for novel oncogenes is important because these could be the target of future specific anticancer therapies. In the present work, we report the identification of novel amplified genes in lung cancer. In order to find out novel amplified genes in lung cancer, we aligned the gene expression ...
ORGANISM(S): Homo sapiens 
2010-04-11 | E-GEOD-21168 | biostudies-arrayexpress
TranscriptomicsThe HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR mutated and wildtype NSCLC cells
The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs), such as erlotinib. Chromatin-modifying agents offer a novel therapy approach by sensitizing tumor cells to TKIs. The NSCLC cell lines HCC827 (EGFR mutant, adenocar...
ORGANISM(S): Homo sapiens 
2014-12-03 | E-GEOD-63784 | biostudies-arrayexpress
GenomicsCCL20 Released by Drug-Tolerant Persisters Impairs Immunotherapy in EGFR-Mutated Lung Adenocarcinoma
CCL20 Released by Drug-Tolerant Persisters Impairs Immunotherapy in EGFR-Mutated Lung Adenocarcinoma
PRJNA1247408 | ENA
ProteomicsEGFR-TKI-down-regulated proteins in HCC827 cells
EGFR mediates stabilities of a wide spectrum of proteins. Treatment of the cells with EGFR tyrosine kinase inhibitors (EGFR-TKIs) leads to degradation of these proteins. To define the proteins and corresponding pathways of EGFR-stabilized proteins, we use mass spectrum to quantify the protein level...
ORGANISM(S): Homo sapiens (Human) 
2025-05-13 | PXD050420 | Pride
Human egfr mutated lung cancer cells 
UnknownRepeated intravenous transplantation of human umbilical cord mesenchymal stem cells does not promote tumorigenesis in EGFR-mutated lung cancer mice.
Not available
S-EPMC12403704 | biostudies-literature
UnknownMusashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).
Not available
S-EPMC7961039 | biostudies-literature
UnknownNotch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
Not available
S-EPMC10067397 | biostudies-literature
UnknownAcquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Not available
S-EPMC6486868 | biostudies-literature
Sort   by:  
 Page size